This event, scheduled for June 10, will focus on whether two psychedelic substances, DOI and DOC, should be classified under strict government control as Schedule I drugs. Opposition from Panacea Plant Sciences Leading the challenge against the DEA’s intentions is David Heldreth, the CEO of Panacea Plant Sciences. Implications of the Hearing on Future Drug Policy The upcoming DEA hearing on DOI and DOC encapsulates the broader debate on the role and regulation of psychedelic substances. DEA’s Rationale and Controversy Despite the resistance, the DEA remains firm on its stance to ban these psychedelic substances, reiterating arguments from past discussions. This discussion follows a year-long contemplation by the DEA and will involve arguments from various groups, including opposition from Panacea Plant Sciences.
The Drug Enforcement Administration (DEA) is gearing up for a significant public meeting. This event, scheduled for June 10, will focus on whether two psychedelic substances, DOI and DOC, should be classified under strict government control as Schedule I drugs. This discussion follows a year-long contemplation by the DEA and will involve arguments from various groups, including opposition from Panacea Plant Sciences.
Opposition from Panacea Plant Sciences
Leading the challenge against the DEA’s intentions is David Heldreth, the CEO of Panacea Plant Sciences. Heldreth disputes the constitutionality of the...
Read the full article @ Marijuana Index